CTOs on the Move

Complete Senior Care

www.completeseniorcare.org

 
Complete Senior Care is a Niagara Falls, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

The Simply Good Foods Company

The Simply Good Foods Company, or “Simply Good Foods”, is the company created by the business combination of Conyers Park Acquisition Corp. and Atkins Nutritionals, Inc. Simply Good Foods will look to expand its platform through investment opportunities in the snacking space and broader food category. Over time, Simply Good Foods will look to become a portfolio of brands that bring simple goodness, happiness and positive experiences to consumers and their families. Simply Good Foods` common stock and warrants are listed on the NASDAQ stock exchange under the symbols “SMPL” and “SMPL.W”, respectively.

American Society of Plastic Surgeons

American Society of Plastic Surgeons is a Arlington Heights, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Iroquois Nursing Home

Iroquois Nursing Home is a Jamesville, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Washington Regional Transplant Consortium

Washington Regional Transplant Consortium is a Annandale, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PanOptica

At PanOptica, our aim is to develop new ocular therapies that help patients see their very best throughout their lives. Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient`s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.